catalyst calendar
GILEAD SCIENCES INC · Data as of 2026-10-25
Feb 2
Announced U.S. Food and Drug Administration ("FDA") accepted a supplemental New Drug Application submission for Yeztugo® (lenacapavir) 300-mg tablets as a potential once-weekly oral formulation for HIV pre-exposure prophylaxis ("PrEP"), with a Prescription Drug User Fee Act target action date of February 2, 2027.Source filing
2026
Gilead Sciences, Inc. (Nasdaq: GILD) will present new findings from its HIV and antiviral research and development programs at IDWeek 2026, taking place October 21-24 in Washington, D.C.Source filing
2026
Gilead Sciences, Inc. (Nasdaq: GILD) will present new findings from its HIV and antiviral research and development programs at IDWeek 2026, taking place October 21-24 in Washington, D.C.Source filing
2026
Gilead Sciences, Inc. (Nasdaq: GILD) will present new findings from its HIV and antiviral research and development programs at IDWeek 2026, taking place October 21-24 in Washington, D.C.Source filing
Nov 5
Sustained Biochemical Efficacy and Safety of Seladelpar in Patients with Primary Biliary Cholangitis, Including Those at High Risk for Progression, up to 5 years of Treatment from ASSURE Abstract #1170 Poster Session November 5, 2026 12:00-1:00 PMSource filing
Nov 7
Characteristics and Outcomes of On-Treatment ALT Flares in Patients with Hepatitis Delta Virus Receiving Bulevirtide and Pegylated Interferon Abstract #3200 Poster Session November 7, 2026 1:00–2:00 PMSource filing
Nov 8
Seladelpar for Alkaline Phosphatase Normalization in Primary Biliary Cholangitis: Results from the IDEAL Phase III Randomized-Controlled Trial Abstract #5007 Oral Presentation November 8, 2026 5:00–5:15 PMSource filing